VC isn't VC anymore – understanding the rise of Cancer Capital

Venture capital has morphed into “Cancer Capital,” with a tiny elite of firms managing tens of billions of dollars, merging private-equity tactics, and earning fees regardless of portfolio success, thereby escaping market and regulatory accountability. This concentration forces the remaining 99% of VCs to operate under the agenda of these dominant funds, shifting power from founders to investors who now dictate political and strategic directions.